One of our clients published preclinical data on NASH-fibrosis on Cellular and Molecular Gastroenterology and Hepatology
We announced that the results of the study in the STAM™ mouse model of NASH has been published in Cellular and Molecular Gastroenterology and Hepatology by Kawasaki Medical School:
Title: “Dipeptidyl Peptidase 4 inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice”
The authors demonstrated that Sitagliptin, a DPP-4 inhibitor, attenuated development of NASH-HCC showing anti-tumor effects.
STAM tumors were most molecularly similar to human HCC and useful for pharmacology studies of anti-cancer drugs in relatively short time compared with other HCC models.